alexa Interleukin-2 Receptor and#945;-chain (CD25) Expression in Acute Myeloid Leukemia | OMICS International
ISSN: 2155-9899
Journal of Clinical & Cellular Immunology

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Interleukin-2 Receptor α-chain (CD25) Expression in Acute Myeloid Leukemia

Kazunori Nakase1,3*, Kenkichi Kita2 and Naoyuki Katayama3

1Cancer Center, Mie University Hospital, Tsu, Japan

2Department of Internal Medicine, Japan Baptist Hospital, Kyoto, Japan

3Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan

*Corresponding Author:
Kazunori Nakase
Cancer Center, Mie University Hospital
2-174 Edobashi, Tsu
Mie 514-8507, Japan
Tel: 81592315296
Fax: 81592315348
E-mail: [email protected]

Received date: May 26, 2016; Accepted date: August 05, 2016; Published date: August 09, 2016

Citation: Nakase K, Kita K, Katayama N (2016) Interleukin-2 Receptor α-chain (CD25) Expression in Acute Myeloid Leukemia. J Clin Cell Immunol 7:444. doi: 10.4172/2155-9899.1000444

Copyright: © 2016 Nakase K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Clinical & Cellular Immunology


Recent studies have shown that cytokine/cytokine receptor systems affect leukemic cell biology and clinical behavior of leukemic patients. Among various cytokine receptors, only interleukin-2 receptor α-chain (IL-2Rα, CD25) expression predicts a poor prognosis of patients (≤ 60 years old) with acute myeloid leukemia (AML). Even in prognostic analyses including unfavorable surface markers and cytogenetics, IL-2Rα is recognized to be an independent adverse indicator in such patients. Assessment of the presence of IL-2Rα should be essential to make therapeutic risk classification of AML patients in a future. However, as the lack of IL-2 responsiveness is observed in AML cells, further investigations are required to clarify the mechanism why IL-2Rα(+) AML patients have a dismal clinical outcome


Interleukin-2 receptor α-chain; CD25; Acute myeloid leukemia


Numerous cytokines, including colony stimulating factors (CSF) and interleukins (IL), affect the biological properties of acute leukemia cells [1]. As cytokines bind to their respective receptors on the cell surface to exert their effect [2], aberrant or excessive expression of cytokine receptors may be closely associated with the pathological status of patients with acute leukemia. However, the expression of various cytokine receptors on acute myeloid leukemia (AML) cells has not yet been extensively evaluated, and the detailed clinical significance of their expression remains to be determined. Investigations into cytokine/cytokine receptor system in AML might provide us clues lead to develop a new therapeutic approach.

Prognostic significance of IL-2Rα expression in AML

Recently, we published a paper regarding prognostic relevance of cytokine receptor expression in AML [3]. Among the cytokine receptors we examined by flow cytometric analysis: interleukin-2 receptor α-chain (IL-2Rα, also known as CD25), IL-2Rβ, IL-3Rα, IL-4Rα, IL-5Rα, IL-6Rα, IL-7Rα, the common β-chain (βc), γc, granulocyte-macrophage (GM)-CSFRα, G-CSFR, c-fms, c-mpl, c-kit, FLT3, and GP130, only IL-2Rα expression was significantly associated with a shorter overall survival in younger adult patients (≤ 60 years old) with AML. These findings were not observed in older patients >60 years old. Although several reports from western countries have also shown that the expression of IL-2Rα correlates with adverse outcome in patients with AML [4-6], this is the first report describing that IL-2Rα is the strongest prognostic indicator among those cytokine receptors. Elevated levels of IL-3Rα correlated with a poor response to conventional chemotherapy, as previously described [7], but, its high expression did not affect the overall survival in patients with AML.

In addition, the prognosis of IL-2Rα(+) AML was poorer than AMLs with known other unfavorable factors such as a white blood cell count ≥ 3 × 104/μl, and the expression of CD4 [8], CD7 [9], CD11b [10], and CD56 [11]. The cytogenetic risk classification currently provides the most powerful prognostic information in AML [12]. This method is used to stratify AML patients into three discrete categories such as the favorable-, intermediate-, and adverse-prognosis groups. However, more than half of AML patients are allocated to the intermediate-risk category, and this group is considered to be biologically heterogeneous and prognostically further distinguishable. By incorporating the IL-2Rα status in this risk classification, a significantly high-risk cohort equivalent to the adverse-risk category was sorted out from the subset with intermediate-risk cytogenetics [3]. These Japanese data are consistent with that demonstrated in western studies [4,5], suggesting no ethnic difference in the prognostic impact of IL-2Rα expression. Therefore, we recommend that IL-2Rα assessment, which is cost-effective and less time-consuming, should be incorporated into current prognostic schema in order to improve AML prognostication.

Why is the prognosis of IL-2Rα(+) AML so poor?

Of note is that leukemia cells from patients with IL-2Rα(+) AML did not respond to IL-2 regardless of the expression levels of IL-2Rα [1]. The IL-2R consists of IL-2Rα, IL-2Rβ, and γc, and the IL-2Rβ/γc complex is responsible for IL-2 signal transduction. Lack of IL-2 responsiveness of IL-2Rα(+) AML cells seemed to be due to the extremely low expression level of IL-2Rβ, as reported previously [13]. Thus, IL-2Rα may have a broader function other than originally proposed as one of growth factor receptors [14].

Among three chains of IL-2R, the IL-2Rα on the cell surface is cleaved by proteolytic processing, and this cleaved chain is detected as serum soluble IL-2Rα (sIL-2R) [15]. Several reports have shown a marked elevation of serum sIL-2R in patients with IL-2Rα(+) AML [16,17]. IL-2Rα on the cell surface of leukemic cells seems to be a considerable portion of the source of sIL-2R [17]. Like cell surface IL-2Rα, as sIL-2R can also bind to IL-2 [18], this free receptor competes with IL-2R on CD8(+) T-cells and natural killer cells for IL-2. For that reason, IL-2 deprivation by sIL-2R could suppress host antitumor immunity in AML [19].

On the other hand, Yang et al. has reported an intriguing analysis regarding the mechanism by which sIL-2R may contribute to a reduced survival in follicular B-cell lymphoma [20]. They described that sIL-2R/IL-2 complex facilitates IL-2 mediated STAT5 phosphorylation, thereby up regulating Foxp3 expression in CD4(+) Tcells. Such cells are shown to differentiate toward to regulatory T-cells and to display increased inhibition of CD8(+) T-cell function. Even in IL-2Rα(+) AML, a similar situation, which could lead to anti-leukemia immune escape status, may be generated in the bone marrow (BM) microenvironment. In relation to the action of STAT5, however, some researchers have suggested that its activation is not sufficient to induce Foxp3 expression [21]. Wuest et al. have demonstrated that Foxp3 is induced by inhibition of histone methyltransferase G9A and reduction of its mediated heterochromatin H3K9me2 [22]. Hence, IL-2 signaling via sIL2R/IL-2 complex might be also associated with the regulation of G9A expression. Additional studies are needed to clarify this issue.

In our study, a close relationship existed between the expression of IL-2Rα and that of adhesion related molecules such as CD4, CD11b, CD11c, and HLA-DR, as well as IL-3Rα [3]. As the presence of IL-3Rα shows a typical feature of leukemia stem cells (LSCs), IL-2Rα appears to be expressed at an immature differentiation level of AML, in agreement with previous observations [5,23]. In addition, we also focus into their phenotypes indicating dendritic cell like characters suitable for cell-adhesion and/or cell-communication. This finding allows us to speculate that IL-2Rα may serve a certain role in the control of cell-tocell interaction [14]. IL-15Rα forms a high-affinity receptor with IL-2Rβ/γc, and IL-15Rα present IL-15 in an intercellular fashion to the IL-2Rβ/γc expressed on neighboring cells [24]. Similarly, it is reported that IL-2Rα on one cell can present IL-2 in trans to IL-2Rβ/γc expressed on another cell to augment IL-2 signaling [25,26]. Thus, IL-2Rα on the cell surface of AML cells coupled to the increased sIL-2R bind to IL-2, and their complex may activate surrounding other cells expressing IL-2Rβ/γc such as CD4(+) T-cells, and tumor associated macrophages [27] to promote a tumor-friendly BM microenvironment (Figure 1). This environmental situation could support the survival of IL-2Rα(+) AML cells. So, minimal residual disease (MRD) after chemotherapy, which leads to disease relapse [28], may be ascribed to these survived IL-2Rα(+) cells. In this context, it is quite interesting that the level of MRD has been demonstrated to correlate with the expression of IL-2Rα on leukemia cells [4] and the frequency of LSCs [29]. Future investigations are expected to validate our hypothesis regarding some critical role of IL-2Rα in the cell-to-cell interaction in the BM microenvironment of AML.


Figure 1: Image of cell-to-cell interaction between AML cell expressing IL-2Rα and surrounding CD4(+) T-cell. IL-2Rα on the cell surface of AML cell coupled to the increased sIL-2R may bind IL-2, and sIL-2R/IL-2 complex activates surrounding CD4(+) T-cell, which differentiates toward to regulatory T-cell in the bone marrow microenvironment. AML: Acute Myeloid Leukemia; IL-2Rα: Interleukin-2 Receptor α-chain; γc: The common γ-chain.

Final Remarks

Among various cytokine receptors, only IL-2Rα had prognostic value which provides an additional marker for better risk stratification of AML patients ≤ 60 years old. IL-2Rα testing should be added into current AML prognostication system. As therapeutic aspect, although 60-80% of AML patients can achieve complete remission after induction chemotherapy, overall survival at 5 years still remains to be as low as approximately 20-30% [30,31]. This eventually poor outcome is due to the difficulty of eradicating leukemia cells and preventing disease relapse. At present, even allogeneic hematopoietic stem cell transplantation shows a limited effect on IL-2Rα(+) AML [32]. Accordingly, establishment of newer therapeutic strategies targeting IL-2Rα are strongly expected to overcome this type of AML by possibly eliminating MRD and/or LSCs.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8560
  • [From(publication date):
    August-2016 - Apr 27, 2018]
  • Breakdown by view type
  • HTML page views : 8470
  • PDF downloads : 90

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version